Arbutus Biopharma(ABUS)
$4.05+0.01 (+0.25%)
ABUS
Arbutus Biopharma stock drug pipeline
$4.05
At close:+0.01 (+0.25%)
Want to see ABUS full AI Analyst Report?
Arbutus Biopharma (ABUS) Drug Pipeline
1,289 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ab-101, Nucleos(T)Ide Analogue | Chronic Hepatitis B | Phase I | Active Not Recruiting | Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. | Jul 14, 2023 | ― |
| Ab-729, Peg-Ifnα-2A | Chronic Hepatitis B | Phase II | Completed | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | Jul 19, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ab-101, Nucleos(T)Ide Analogue | Phase I | Chronic Hepatitis B | Active Not Recruiting | Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. | Jul 14, 2023 | ― |
| Ab-729, Peg-Ifnα-2A | Phase II | Chronic Hepatitis B | Completed | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | Jul 19, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Arbutus Biopharma (ABUS) have in its pipeline
Arbutus Biopharma ABUS is currently developing the following drugs: Ab-101, Nucleos(T)Ide Analogue, Ab-729, Peg-Ifnα-2A. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

